Pharmasset was acquired by Gilead in 2011 for $11 billion for their oral therapeutics for the treatment of hepatitis C virus (HCV) and human immunodeficiency virus (HIV).
Ception Therapeutics was acquired by Cephalon Inc. in March 2010 in a deal worth $350 million plus significant future millstones. Cephalon was subsequently acquired by Teva in 2011.
Lumira was an early investor in MAKO Surgical prior to its IPO and later when it was acquired by Stryker for $1.65 billion in 2013 for its minimally invasive robotic surgical arm for partial knee and total hip arthroplasty.
Alveolus, developer of next generation non-vascular interventional stent technology for use in the lungs, was acquired by Merit Medical Systems Inc. in February 2008.
Corus Pharmaceuticals, developer of Aztreonam for treatment of cystic fibrosis and Lidocaine for treatment of oral corticosteroid dependent asthma, was acquired by Gilead in August 2006 for $365 million.
Lumira Ventures led a PIPE in Depomed in 2003 and fully exited in 2006 after the FDA approved the company’s two lead products in 2005.
Guava Technologies was acquired by Millipore Inc. in February, 2009.
From the time we invested in 2002 to our exit in 2006, ISTA launched three products in the United States to treat diseases of the eye.
KAI Pharmaceuticals, developer of novel therapeutics for kidney disease, was acquired by Amgen in 2012 for US$315 million.
Morphotek, developer of therapeutic antibodies for the treatment of cancer, inflammatory and infectious diseases, was acquired by Eisai in April 2007 for $325 million.
Resonant Medical, developer of 3D ultrasound image-guided radiotherapy products, was acquired by Elekta in May of 2010.
Automated Breast Ultrasound company U-Systems was acquired by GE healthcare in late 2012.
Aurinia Pharmaceuticals is a clinical stage pharmaceutical company focused on the global nephrology market. Its lead drug, voclosporin, is a novel calcineurin inhibitor being developed for the treatment of Lupus Nephritis.
BAROnova is developing a novel, non-surgical device for the treatment of obesity. It consists of a TransPyloric Shuttle device that is inserted into the stomach using a simple, 10-minute endoscopic procedure.
Endotronix, Inc., a digital health medtech company, is developing an integrated platform to provide comprehensive, reimbursable health management tools for patients suffering from advanced heart failure.
KisoJi Biotechnology Inc. is an early stage life science company engaged in the development of antibodies for the treatment of various cancers.
Based in Montreal, OsteoQC is developing new drug candidates for the treatment of bone-related diseases.
Swift Medical is a leader in imaging technology and data analytics solutions for the healthcare industry. Swift Wound, together with Swift’s Metrics dashboard, represents a new generation in wound care management technology.
Zymeworks is a biotherapeutics company that is developing best-in-class Azymetric™ bi-specific antibodies and antibody drug conjugates for the treatment of cancer, autoimmune and inflammatory diseases.